Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Breast cancer drugs should be offered to healthy but high risk women, US panel concludes.

McCarthy M.

BMJ. 2013 Apr 18;346:f2499. doi: 10.1136/bmj.f2499. No abstract available.

PMID:
23599364
2.

Exemestane is effective for the chemoprevention of breast cancer.

Barton MK.

CA Cancer J Clin. 2011 Nov-Dec;61(6):363-4. doi: 10.3322/caac.20131. Epub 2011 Sep 6. No abstract available.

3.

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.

Kondo M, Hoshi SL, Toi M.

Br J Cancer. 2009 Jan 27;100(2):281-90. doi: 10.1038/sj.bjc.6604869. Epub 2009 Jan 13.

4.
5.

Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.

Olevsky OM, Martino S.

Menopause. 2008 Jul-Aug;15(4 Suppl):790-6. doi: 10.1097/gme.0b013e31817e6683.

PMID:
18596600
6.

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM.

Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Review.

PMID:
19020189
7.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

8.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
9.

Experts add second drug to breast cancer prevention regimen.

[No authors listed]

Harv Womens Health Watch. 2013 Oct;21(2):8. No abstract available.

PMID:
24432457
10.

Chemoprevention of breast cancer in postmenopausal women.

Geller BA, Vogel VG.

Breast Dis. 2005-2006;24:79-92. Review.

PMID:
16917141
11.

Exemestane for primary prevention of breast cancer in postmenopausal women.

Zhang Y, Simondsen K, Kolesar JM.

Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585.

PMID:
22855103
12.

Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr.

Cancer. 2000 May 1;88(9):2047-53.

PMID:
10813716
13.

Chemoprevention in postmenopausal women.

Rastogi P.

Menopause. 2008 Jul-Aug;15(4 Suppl):810-5. doi: 10.1097/gme.0b013e318178863e. Review.

PMID:
18596603
14.

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

Jordan VC, Gapstur S, Morrow M.

J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review.

15.

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N.

Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5. doi: 10.1016/j.ajog.2011.06.067. Epub 2011 Jun 24.

PMID:
21872200
16.

[From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].

Kreienberg R, Kafka A.

MMW Fortschr Med. 2003 Jun 12;145(24):32-3. German. No abstract available.

PMID:
12866296
17.

Raloxifene (Evista) for breast cancer prevention in postmenopausal women.

[No authors listed]

Med Lett Drugs Ther. 2006 May 8;48(1234):37.

PMID:
16685245
18.

Tamoxifen and raloxifene may benefit women at high risk for breast cancer.

Rollins G.

Rep Med Guidel Outcomes Res. 2002 Jul 26;13(14):1-2, 5. No abstract available.

PMID:
12518771
19.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
20.

Drugs can reduce the incidence of breast cancer: now what?

Wozniak TF, Eppes PG, Wilson CT.

Del Med J. 1999 Sep;71(9):387-9. No abstract available.

PMID:
10584440
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk